Quality of care in patients with type 1 diabetes during the COVID-19 pandemic: a cohort study from Southern Brazil

Table 2 Number of patients who presented the quality of care indicators for type 1 diabetes mellitus according to the guidelines in the two periods evaluated (n = 289)

Quality of care indicator	2019	2020	P-value*
Assessment of distal simetric diabetic neuropathy	152 (52.8)	119 (41.3)	0.004
Assessment of albuminuria and / or serum creatinine^a	247 (86.1)	206 (71.8)	< 0.001
Albuminuria (mg)	6.0 (3.0–18.0) 0.9 (0.7–1.0)	6.0 (4.0–14.0) 1.0 (0.8–1.2)	0.93 < 0.001
Mean creatinine (mg/dl)
HbA1c^a	263 (91.6)	135 (47.0)	< 0.001
Number of exams done	3 (2–3)	1 (1–2)	< 0.001
HbA1c value (%)	8.6 (7.8–9.8)	8.6 (7.6–9.6)	0.12
HbA1c value (mmol/mol)	70.0 (62.0–84.0)	70.0 (60.0–81.0)
Lipid profile^a	242 (84.3)	266 (92.7)	< 0.001
Total cholesterol (mg/dl)	173.0 (151.0–200.0)	178.0 (152.0–209.0)	< 0.001
HDL cholesterol (mg/dl)	56.0 (46.2–67.0)	53.0 (45.0–64.2)	< 0.001
LDL cholesterol(mg/dl)	101.0 (77.3–124.5)	104.8 (82.5–128.9)	< 0.001
Triglyceride (mg/dl)	78.5 (58.8–112.0)	81.0 (60.5–108.0)	0.39
Retinopathy assessment^b	172 (63.9)	83 (30.9)	< 0.001
Thyroid-stimulating hormone assessment	262 (91.6)	256 (89.5)	0.080

Data presented as number (%) for categorical variables or median and interquartile range or mean and SD for continuous variables
HbA1c glycated hemoglobin, HDL high density lipoproteins, LDL low density lipoproteins
^aNumber of tests assessed and median values based on the number of patients who presented quality of care indicators each year
^bFive years of diagnosis: n = 271
^*The p-value is given for the McNemar test for categorical variables and the Wilcoxon test for continuous variables

ISSN: 1758-5996